dc.contributor.author | Schrijver, LH | |
dc.contributor.author | Olsson, H | |
dc.contributor.author | Phillips, K-A | |
dc.contributor.author | Terry, MB | |
dc.contributor.author | Goldgar, DE | |
dc.contributor.author | Kast, K | |
dc.contributor.author | Engel, C | |
dc.contributor.author | Mooij, TM | |
dc.contributor.author | Adlard, J | |
dc.contributor.author | Barrowdale, D | |
dc.contributor.author | Davidson, R | |
dc.contributor.author | Eeles, R | |
dc.contributor.author | Ellis, S | |
dc.contributor.author | Evans, DG | |
dc.contributor.author | Frost, D | |
dc.contributor.author | Izatt, L | |
dc.contributor.author | Porteous, ME | |
dc.contributor.author | Side, LE | |
dc.contributor.author | Walker, L | |
dc.contributor.author | Berthet, P | |
dc.contributor.author | Bonadona, V | |
dc.contributor.author | Leroux, D | |
dc.contributor.author | Mouret-Fourme, E | |
dc.contributor.author | Venat-Bouvet, L | |
dc.contributor.author | Buys, SS | |
dc.contributor.author | Southey, MC | |
dc.contributor.author | John, EM | |
dc.contributor.author | Chung, WK | |
dc.contributor.author | Daly, MB | |
dc.contributor.author | Bane, A | |
dc.contributor.author | van Asperen, CJ | |
dc.contributor.author | Gómez Garcia, EB | |
dc.contributor.author | Mourits, MJE | |
dc.contributor.author | van Os, TAM | |
dc.contributor.author | Roos-Blom, M-J | |
dc.contributor.author | Friedlander, ML | |
dc.contributor.author | McLachlan, S-A | |
dc.contributor.author | Singer, CF | |
dc.contributor.author | Tan, YY | |
dc.contributor.author | Foretova, L | |
dc.contributor.author | Navratilova, M | |
dc.contributor.author | Gerdes, A-M | |
dc.contributor.author | Caldes, T | |
dc.contributor.author | Simard, J | |
dc.contributor.author | Olah, E | |
dc.contributor.author | Jakubowska, A | |
dc.contributor.author | Arver, B | |
dc.contributor.author | Osorio, A | |
dc.contributor.author | Noguès, C | |
dc.contributor.author | Andrieu, N | |
dc.contributor.author | Easton, DF | |
dc.contributor.author | van Leeuwen, FE | |
dc.contributor.author | Hopper, JL | |
dc.contributor.author | Milne, RL | |
dc.contributor.author | Antoniou, AC | |
dc.contributor.author | Rookus, MA | |
dc.contributor.author | EMBRACE, GENEPSO, BCFR, HEBON, kConFab, and IBCCS, | |
dc.date.accessioned | 2019-09-17T09:48:41Z | |
dc.date.issued | 2018-04-01 | |
dc.identifier.citation | JNCI cancer spectrum, 2018, 2 (2), pp. pky023 - ? | |
dc.identifier.issn | 2515-5091 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3342 | |
dc.identifier.eissn | 2515-5091 | |
dc.identifier.doi | 10.1093/jncics/pky023 | |
dc.description.abstract | BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. RESULTS: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). CONCLUSIONS: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed. | |
dc.format | Electronic-eCollection | |
dc.format.extent | pky023 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | OXFORD UNIV PRESS | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | EMBRACE, GENEPSO, BCFR, HEBON, kConFab, and IBCCS | |
dc.title | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-24 | |
rioxxterms.versionofrecord | 10.1093/jncics/pky023 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
rioxxterms.licenseref.startdate | 2018-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | JNCI cancer spectrum | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.publication-status | Published | |
pubs.volume | 2 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Oncogenetics | |
dc.contributor.icrauthor | Eeles, Rosalind | |